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Allergic asthma is a common pathology in children and house dust mites are the most
frequent indoor allergens implicated 1. The Global Initiative for Asthma (GINA) guidelines
has defined the management of allergic asthma, which recommends the association of
allergen  avoidance,  pharmacologic  treatment  and  allergen  immunotherapy,  when
indicated 2.
Immunotherapy is  a specific  therapeutic  approach in the treatment  of  allergic  airway
disease and insect  venom allergy  and has been utilized for  decades:  it  is  therefore
recommended to start it as soon as possible in allergic children to modify the natural
course  of  respiratory  allergy.  Specific  immunotheraphy  (SIT)  has  been  shown to  be
effective  in  reducing  asthmatic  symptoms,  medication  use  and  bronchial  hyper-
responsiveness  3-4.  Additionally,  it  has  been  recently  shown  that  specific
immunotherapy can be also used to prevent the occurrence of  new sensitizations to
airborne allergens in children exclusively sensitized to house dust mites 5-6. However,
subcutaneous administration of SIT is inconvenient, time and resource consuming and is
occasionally  associated  with  severe  systemic  side  effects  despites  the  guidelines
developed for its use 7. On the other hand, sublingual immunotherapy (SLIT), which has
been developed over the past 20 years, offers a better safety profile and ease of use.
These advantages make it an attractive option for children 8-9.
The aim of this article is to review current knowledge related to SLIT in children allergic
to mites and to identify needs for future research in this field.
Indications and contraindications for SLIT in children are not well established at present,
anyway,  as  well  as  SCIT,  the  specific  diagnosis  of  an  immunoglobulin  E-mediated
allergic  disorder  is  a  necessary  prerequisite.  Immunotherapy  is  indicated  as  a
supplement to allergen avoidance, to pharmacotherapy and to patient/parent education.
Efficacy and safety  of  SLIT have been demonstrated in  adult,  particularly  in  pollen-
associated allergic rhinoconjunctivitis 10-11-12. Due to methodological problems, studies
are  not  comparable  as  they  were  performed  using  different  products,  allergen
concentrations,  doses and duration  of  the  treatment.  Some studies  in  children have
shown an effect in rhinitis and asthma in house dust mite sensitive children 13-14-15.
Moreover,  in  paediatric  patients  affected  by  allergic  rhinitis  SLIT  was  found  to  be
clinically effective with pollens but not with mites 11. Conversely, when administered to
children suffering from allergic asthma, it was found that SLIT with mites extracts has a
greater efficacy as compared to SLIT with pollens 16.
Nevertheless,  the  evidence in  childhood is  little  less  convincing  and more  data  are
needed,  derived from large-population-based high  quality  studies.  In  fact  the  clinical
relevance, long-term results and the size of the effect, as well as the dose, the treatment
regimen and the duration have not been sufficiently elaborated.
Mechanisms of SLIT.  The mucosal antigen presenting cells pick up the allergen in the
oral mucosa 17. After the application of SLIT, a rise in serum IgG4 18-19, but lower than
that observed in SCIT, and a down-regulation in Der-p-1-specific IgE production 20 and
in ICAM-1 expression by nasal epithelial cells have been demonstrated 22. It has been
also shown that SLIT is able to avoid the spontaneous increase in nasal IgE and in nasal
tryptase after one year of treatment 21.
The induction of  tolerance is thought to be mediated by T-reg cells  and IL-10 23. A
recent  study  reports  that  IL-18  and  signalling  lymphocytic  activation  molecule  are
up-regulated  during  SLIT  suggesting  that  the  Th2  type  inflammatory  response  is
down-regulated by an increase Th1 type response 24. According to this, Barberi et al.
reported that 2-year SLIT is capable of inducing immunologic hyporeactivity to mites with
a  significant  IL-10  increase  and  an  important  decrease  of  Th2-dependent
pro-inflammatory  cytokines  25.  Another  study  showed that  after  12  months  of  SLIT,
mature dendritic cells derived from SLIT-treated patients showed a statistically significant
defect of CD86 up-regulation, an increase of IL-10, and a reduction of IL-12 production.
SLIT induces changes in DCs functions that might be responsible for an impairment of T
cell  activation  or  drive  T  cells  towards  a  regulatory  activity,  thus  restoring  immune
tolerance to allergens 26.
Efficacy in allergic rhinitis
Most of the data on the efficacy of SLIT has been generated in adults and safety and
tolerability  data seem to be convincing for grass pollen tablet.  The efficacy for other
allergens is  not  as  well  proven.  A Cochrane review has been published on SLIT in
patients  with  allergic  rhinitis  12.  It  concluded  that  SLIT  is  a  safe  treatment,  which
significantly reduces symptoms and medication requirements in pollen-induced rhinitis,
but there is less significant efficacy in house dust mites-induced rhinitis and the degree
of this benefit  compared to other available therapies such as SCIT is not clear.  Two
paediatric meta-analyses 11-27 suggest that SLIT is more effective than suggested by
the previous Cochrane reviews, but in those analysis it was not possible to compare the
effect of different allergens. Many other studies investigating SLIT and allergic rhinitis
have  not  demonstrated  a  major  effect,  failing  to  show a  benefit  14-15-28-29-30-31.
Further trials have reported efficacy and tolerability of house dust mite SLIT also using
high dose 32.
Efficacy in allergic asthma
Until  recently  only  few  studies  15-33  were  performed  with  conflicting  results.  Two
meta-analysis 27-34 demonstrated a clinical benefit of SLIT with significant reduction in
symptoms and medication use. However, a third meta-analysis has demonstrated only a
small improvement on asthma severity 34. Also two trials demonstrated improvement to
bronchial challenge 35-36, but two did not 37-38. Another trial failed to show any effect in
92 mite-sensitive asthmatic children 39. In a recent meta-analysis on paediatric allergic
asthma it was concluded that SLIT reduces both symptom score and rescue medication
use when compared to placebo 10. The effect was found particularly with house dust
mite allergen extracts.
No relevant studies comparing SLIT and SCIT in children have been published.
Two studies, in which the combination of SLIT and SCIT have been analysed, concluded
that this option may produce a better efficacy than SCIT alone in the improvement of
symptoms and pulmonary function and it successfully combines the advantages of the 2
alternatives: rapid onset and potency in SCIT and safety and avoidance of injections in
SLIT. 40
In the matter of preventive effects of SLIT in children sensitized to house dust mites, a
recent  non-randomized  parallel  group  open  study  with  SLIT for  5  years  indicated  a
preventive effect of SLIT as regards development of new sensitivities 41.
Conclusion
Immunotherapy is indicated for patients with IgE-mediated allergy to house dust mites
confirmed by a specific diagnosis such as Skin Prick Test and/or specific IgE dosage,
because of its immunological influence demonstrated by deviation of the immunological
response to allergens toward production of Treg-dependent cytokines, such as IL-10 and
TGF- . The relevance of IL-10 as an early marker of successful immunotherapy has
been further highlighted. Safety of SLIT has been demonstrated in further studies, but
also some case reports of adverse effects (oral mucosal symptoms, itching of the nose
and the  eyes,  asthma or  gastrointestinal  symptoms and anaphylactic  reaction)  have
been reported in  recent  literature.  However,  to  date it  is  not  possible to  confirm the
efficacy of SLIT in children population due to the modest level of methodological quality
together  with  the  publication  bias,  the  high  inter-study  heterogeneity,  the  difference
doses administrated and the small sample size, represent the main interfering factors in
this evaluation.
More data in children population are needed about SLIT’s efficacy, before this treatment
can be strongly recommended.
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